ESR1 and neoplasm: Furthermore, this study shows that pCR is only in highly proliferating breast cancers, like triple negative breast cancer (TNBC), HER2 enriched (HER2 positive plus ER negative), or luminal B/HER2-negative tumours, a good prognostic value, whereas in luminal A and luminal B (ER plus HER2 positive) tumours the pCR is not able to discriminate between good and poor prognosis [13, 14].